Propanc Biopharma Engages CDMO for GMP Production of PRP
Propanc Biopharma announced that a contract and development manufacturing organization, or CDMO, has been engaged for the GMP manufacture of the company's lead asset, PRP, for the upcoming Phase 1b, first-in-human study in 30- 40 advanced cancer patients suffering from solid tumors. Based in Europe, the CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in decoding biologics production providing services of cell line generation, banking and characterization, analytical development, process development and batches production of both drug substances and drug products.
